FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1+ NSCLC
The FDA has approved repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.
The FDA has approved repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.
I would feel deeply uncomfortable if patients ‘chose’ to die because care that would make life worth living was unavailable, says palliative care doctor Rachel…
The call for rigor by van Elk and Fried 1 is a welcome contribution to psychedelic research. The authors emphasized the well-known principles of internal,…
Addiction is an SSA journal publishing peer-reviewed research reports on pharmalogical and behavioural addictions spanning many different disciplines.
Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.
C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and…
The writer of The New York Trilogy, Leviathan and 4 3 2 1 – known for his stylised postmodernist fiction – has died from complications…
Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses how advancements in precision medicine have improved outcomes for patients with brain metastases.
Systemically administered mRNA aggregates (RNA-LPA) transfect lymphoreticular organs, inducing a massive cytokine/chemokine response that rapidly reprograms the tumor microenvironment while mobilizing dendritic cells/lymphocytes to elicit…
Neeraj Agarwal: The latest in the mHSPC prostate cancer / AUA24, cancer, MedscapeLIVE, mHSPC treatment, Neeraj Agarwal, OncoDaily, Oncology, prostate cancer,
The FDA has granted breakthrough therapy designation to ziftomenib for the treatment of NPM1-mutant acute myeloid leukemia.